Coherus BioSciences (CHRS) Misses Q3 EPS by 1c, Misses on Revenue
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.34 +16.52%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $13.36 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Freedom Broker Downgrades Flexsteel (FLXS) to Hold
- 374Water Inc (SCWO) Misses Q2 EPS by 15c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
